WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices. The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading. Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court. |
Mom is arrested after leaving her son, 8, and daughter, 6, in her highChina's Qingming holiday box office hits record high2nd Hong Kong pop culture festival to open on April 6China's railways handle 16.47M passenger trips on MondayCambodia plans to add 7 tangible, 3 intangible cultural properties to UNESCO's heritage listing: PMMom is arrested after leaving her son, 8, and daughter, 6, in her highChina's tourism industry witnesses surge in runDisneyland rides on its swift successesSeveral gun bills inspired by mass shooting are headed for final passage in MaineNadal confirms comeback at Barcelona Open